QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Mutual Recognition Procedure (MRP)

Test your understanding of the concepts covered by Mutual Recognition Procedure (MRP): How It Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What remains necessary after the coordinated European phase of an MRP is completed?

No further regulatory work because the procedure is centrally effective Appropriate national implementation and management of the resulting national authorisations A second DCP for each CMS Replacement of all national authorisations by an RMS certificate

Question 2 of 10 A company describes an MRP as a process that creates one European marketing authorisation valid in all participating countries. What is the professional correction?

That description is correct if the RMS has completed the assessment MRP creates a centralised authorisation only for products with safety concerns MRP coordinates recognition of an assessment but results in separate national marketing authorisations MRP creates a Union authorisation only when more than two CMSs participate

Question 3 of 10 An MRP results in a change to a warning concerning an important identified risk. What should the MAH do from a pharmacovigilance perspective?

Treat the change as purely commercial because it arose through an authorisation procedure Assess the change within relevant PV processes and ensure safety-information records and implementation remain consistent Wait until the next periodic safety report before recording the change Remove the warning from the central safety database to avoid country discrepancies

Question 4 of 10 In an MRP, what is the role of the Reference Member State?

It is the Member State whose existing assessment forms the basis for recognition It is the Member State that grants the Union marketing authorisation It is the Member State responsible only for pharmacovigilance oversight It is always the Member State with the largest patient population

Question 5 of 10 Under the article's framework, when may a Member State seek to prevent normal recognition through the formal disagreement mechanisms?

Whenever it prefers a different administrative format Whenever any minor wording difference exists in national product information When the applicable legal conditions are met, including a potential serious risk to public health Whenever the MAH has not yet launched the product commercially

Question 6 of 10 Which statement best characterises the QPPV's role in an MRP?

The QPPV automatically owns and directs the entire MRP The QPPV has no role because MRP is exclusively regulatory The QPPV should oversee relevant pharmacovigilance consequences without being assumed to own the broader regulatory procedure The QPPV replaces the RMS for all safety-related assessment activities

Question 7 of 10 A CMS asks the MAH to clarify an aspect of the submitted dossier. What is the most appropriate initial regulatory interpretation?

The question is automatically a formal objection preventing recognition The question is a routine issue that should be addressed with a direct, evidence-supported response unless it develops into a formal unresolved concern The question must be ignored because CMSs have no substantive role The question automatically triggers the Article 29(4) procedure

Question 8 of 10 Which regulatory source should generally take precedence when resolving a question in a live MRP?

An undated internal summary prepared for training purposes A commercial launch plan The current applicable legislation and legally operative procedure-specific or national documents An old secondary article that describes a previous procedural practice

Question 9 of 10 A company plans an MRP for a product authorised nationally several years ago. Which preparatory activity is most important before relying on the old assessment?

Assume the original dossier automatically represents the current authorised product Reconstruct the current authorised position and relevant regulatory history, including later changes Remove all historical documents to avoid confusion during CMS review Replace the RMS assessment with a new centralised assessment

Question 10 of 10 What is the legal nature of the authorisations resulting from a successful MRP?

A single Union marketing authorisation A collection of coordinated national marketing authorisations in the participating Member States A temporary scientific opinion without legal effect A single RMS authorisation that automatically replaces all national licences

QPPV.com

Professional Knowledge Assessment: Mutual Recognition Procedure (MRP)

Cookie Settings